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ABSTRACT
Lesotho introduced tenofovir disoproxil fumarate (TDF) for first-line antiretroviral treatment (ART) in 2008. The use of TDF has been 
associated with renal toxicity. The study utilised an analytical design to compare retrospective creatinine clearance (CrCl) data 
of 312 antiretroviral treatment naïve adults exposed to TDF and 173 unexposed patients. Impaired renal function was defined as 
CrCl<50 ml/min calculated using the Cockcroft-Gault equation. In fifty-six patients (17.9%) TDF was found to be contraindicated. 
The use of TDF was marginally significant factor for renal toxicity (p=0.054) in univariate analysis, but was insignificant (p=0.122) 
in multivariate logistic analysis. Univariate (p<0.1) and multivariate logistic regression (p<0.05) were performed using STATA® 11. 
Female gender (p=0.016), hypertension (p=0.009), and age > 60 (p=0.004) were significantly associated with CrCl<50 ml/min 
outcome. TDF is a weak contributing factor to renal impairment. Routine baseline renal function screening should be adopted to 
prevent patients with impaired renal function receiving TDF.
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INTRODUCTION
The assessment of renal function in patients on tenofovir diso-
proxil fumarate (TDF) is important because TDF has been as-
sociated with renal toxicity[1]. This is of particular importance 
in Lesotho because the success of ART programmes in Lesotho 
depends on the performance of the drug TDF which currently 
forms the backbone of first-line ART drugs. 
The Government of Lesotho switched most of the patients on 
stavudine-based antiretroviral drug regimens to TDF-based 
regimens as recommended by the World Health Organisation 
(WHO) in 2008[2,3]. Since then, TDF has become the preferred 
first line regimen for antiretroviral treatment of human immu-
nodeficiency virus (HIV) infection in Lesotho. Renal function 
outcomes following the use of TDF had not been studied at 
Roma Health Service Area. 
Numerous studies report that TDF is generally safe to use with 
respect to nephrotoxicity[4-6]. The most common conclusions 
from the studies that justify the use of TDF, state that TDF-as-
sociated nephrotoxicity is a rare event and that nephrotoxicity 
on exposure to TDF may be linked to pre-existing renal disor-
ders[4-6]. Current international guidelines contraindicate use of 
TDF when creatinine clearance falls below 50 ml/min[7].
In contrast, various studies have found evidence of renal proxi-
mal tubule injury and glomerular toxicity[8-10]. in non-predis-
posed patients. In Senegal, patients on TDF had higher rates of 
transition from mild to moderate renal insufficiency[11]. In the 
USA[1] and in Thailand,[12] TDF-exposed groups had significantly 
higher incidences of renal disorder compared to TDF-unex-
posed groups. The use of TDF in HIV is therefore controversial 
because of the possible renal damage. 
The aim of the study was to compare renal function outcomes 
between patients on TDF-based ART regimens and the patients 
on non-TDF-based ART regimens and to determine the variables 
associated impaired renal function outcomes (CrCl<50 ml/min).
METHODOLOGY
Study design and setting
This study utilised an analytical design to compare retrospective 
data for renal function outcomes of patients on TDF-based ART 
and patients on non-TDF-based ART. 
The study was carried out at Roma Health Service Area (RHSA) 
that serves about 6% of Lesotho's population[13]. Lesotho is a 
small landlocked country completely surrounded by South 
Africa. The RHSA is serviced by St Joseph’s Mission Hospital 
and five satellite health centres. Patients at St Joseph’s Mission 
Hospital and at Nazareth Health Centre made up 80% of the 
4,116 HIV patients on ART in the entire RHSA. The study in-
cluded adult HIV patients enrolled on ART between December 
2006 and December 2012 at St Joseph’s Mission Hospital and 
at Nazareth Health Centre.
Assuming an estimated odds ratio of 2 at 95% confidence level 
and a relative precision of 25%, a minimum sample size of 816 
was required. However, only 485 patients met the set inclusion 
criteria from the two centres. 
The study included non-pregnant adult patients who had at 
least one baseline creatinine value recorded while still ART-
naïve, and had been on TDF or non-TDF based ART for at least 
six months. 
Data collection and analysis
The study was approved on 13 of January 2012 by the Ministry 
of Health and Social Welfare of Lesotho. 
Data was collected using pre-designed Microsoft Access® 2007 
(Microsoft Corporation, Redmond, USA) data collection tool 
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which was piloted at St Joseph’s Mission Hospital. No personal 
information was captured into the data collection tool. De-
mographic data, diagnoses, treatments and laboratory values 
of HIV-positive patients were extracted from patient medical 
records. Baseline data included weight, age and gender; base-
line ART regimen, WHO clinical stage, blood pressure, CD4 
count, serum creatinine, blood urea nitrogen, full blood count, 
differential count, and liver function test. Hypertension was de-
fined according to standard guidelines[14].
Data was analysed using STATA® version 11 (StataCorp, Texas, 
USA). Sub-optimal renal function outcome was defined as se-
rum creatinine clearance below 50 ml/min[7]. Creatinine clear-
ance was calculated using the Cockcroft-Gault equation[10]. For 
analysis of baseline renal function and renal function outcomes, 
CrCl values were also categorised according to Chronic Kidney 
Disease (CKD)[15] stages. Unfortunately, patient height was not 
collected. Therefore the body mass index (BMI) could not be 
calculated and was not used as a distinguishing factor in the 
study. 
Summary statistics which included mean, median and inter-
quartile ranges of the patients’ clinical profiles at baseline and 
at six-month intervals were analysed for significance of the dif-
ferences between the TDF and the non-TDF groups using the 
t-test and Fisher’s exact test. 
Univariate and multivariate logistic regression analyses were 
done to determine significant variables associated with creati-
nine clearance less than 50 ml/min. Predictors with p-values less 
than 0.1 in the univariate analysis were included in multivariate 
logistic regression analysis. Significant variables (p<0.05) were 
selected to remain in the final regression model. 
RESULTS
Out of the 485 patients, 173 (36%) fell in the control group 
(non-TDF), while 312 (64%) fell in test group (TDF group).
The ages of the study population ranged from 20 to 78. Age was 
normally distributed both in the TDF and the non-TDF groups. 
The median age was not statistically different between the two 
groups (p=0.235). However, the 30-39 age group was the larg-
est. There were no statistically significant differences in gender 
distribution (Table 1) between the TDF and the non-TDF group 
(p=0.258). 
The baseline weight in the TDF group was significantly 
(p<0.001) lower than the baseline weight in the non-TDF group 
(Table 1). Baseline CD4 count of patients in the TDF group was 
significantly higher than the baseline CD4 counts in the non-
TDF group (p=0.029). Tuberculosis was significantly (p=0.006) 
more common in the TDF group than in the non-TDF group.  
When the baseline CrCl values were categorised according to 
CKD stages, there were no significant differences in baseline 
renal function between the TDF and the non-TDF group. 
Variables associated with impaired renal function at baseline 
and during follow up
The baseline renal function did not differ between sexes 
(p=0.078). There was no association with decreased baseline 
CD4 counts (<50 cells/mm3) and WHO clinical stage and base-
line renal function (p=0.575; and p=0.913 respectively). Patient 
age of 60 and above (p<0.001), as well as hypertension[14] 
(p<0.001), were strongly associated with impaired baseline 
renal function (CrCl<50 ml/min). 
From a baseline median of 69 ml/min (IQR 55-84), renal func-
tion improved by a median change of +4 ml/min at 12 months 
to a median of 73 ml/min (IQR 57-92) and by another median 
change of +2 ml/min at 24 months. However, 10 patients (2.1%) 
had severe impairment; and three patients had end-stage renal 
disease. 
The number of patients who had impaired renal function 
(CrCl<50 ml/min) outcome (19.3%, n=312) in the TDF group 
Table 1: Clinical profile of the study population
Baseline (BL) characteristic Non-TDF Group (n=173) TDF Group (n=312) P-value
Age, median + (IQR) 42 + (17) 38 + (16) 0.235
Gender
           male 63 (36.4%) 130 (41.7%) 0.258
           female 110 (63.6%) 182 (58.3%) 0.258
Weight (kg) + (IQR) 56.1+ (15.6) 54.0 + (12.0) < 0.001** 
WHO stage
           Stage I – III 165 (95.4%) 299 (95.8%) 0.819
           Stage IV 8 (4.6%) 13 (4.2%) -
CD4 count: median (IQR) 142+ (133.0) 167 + (180.5) 0.029**
Hypertension stage I or II 24 (17.5%) 53 (20.4%) 0.593
Tuberculosis 12 (6.9%) 49 (15.7%) 0.006**
Creatinine Clearance
           Median CrCl (IQR) 70.0 + (35.0) 70.0 + (28.0) 0.318
           CrCl < 50 ml/min 32 (18.5%) 56 (17.95%) 0.902
CrCl = serum creatinine clearance; IQR = inter-quartile range; CD4 count is in cells/mm3; ** = Significant p-value.
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was significantly higher (p=0.043) than the number of patients 
with impaired renal function outcome (12.4%, n=173) in the 
non-TDF group. When baseline renal function was controlled 
by excluding patients with impaired baseline renal function 
(CrCl<50 ml/min), the number of patients with impaired renal 
function outcome in the TDF group (12.5%, n=312) remained 
significantly higher (p=0.030) than the number of patients with 
impaired renal function outcome (5.8%, n=173) in the non-TDF 
group.
When improved renal function outcome was considered 
(CrCl>50 ml/min), 12.1% of the patients in the non-TDF group 
had an improved renal function outcome compared to 10.9% in 
the TDF group. When changes decrease in CrCl were compared 
between the groups, the TDF group had a marginally significant 
proportion of patients whose mean CrCl values dropped by 
25% or more from the baseline (p=0.069). 
Overall, more patients in the TDF group had a impaired base-
line renal function outcome (40 or 12.5%) compared to the 
improved outcome (34 or 10.9%). In the non-TDF group, more 
patients had an improved renal function outcome (21 or 12.1%) 
compared to impaired renal function outcome (11 or 5.8%). 
Although improved and impaired outcomes occurred in both 
groups, the TDF group had a higher inclination towards the 
negative outcome. 
Table 2 presents results for univariate (Unadjusted Odds Ra-
tio) and multivariate (Adjusted Odds Ratio) logistic regression 
analysis. In the univariate logistic regression analysis, the vari-
ables that had higher odds of predicting impaired renal func-
tion outcomes were: (1) use of TDF (OR=1.7); (2) age of 60 or 
higher (OR=14.2); (3) female gender (OR=2.1); (4) hypertension 
(OR=2.8); and (5) baseline renal insufficiency (OR=4.2).
When multivariate regression analysis was performed, a number 
of significant variables remained in the final model (Table 2). 
The significant variables included old age, especially ages 
over 60 (p=0.004), female gender (p=0.016), and hypertension 
(p=0.009). Although the use of TDF had higher odds ratio of de-
veloping impaired CrCl outcome (adjusted OR=1.5) compared 
to the non-TDF group, the use of TDF became insignificant in 
the final adjusted model (p=0.122). When odds ratios (OR) 
were considered, older ages above 60 had the highest odds 
ratio (adjusted OR=9.1) of having CrCl<50 ml/min.
DISCUSSION
Although there was no significant difference between the TDF 
and the non-TDF group with respect to age (p=0.235), the 
30-39 age group constituted more than one-third of the study 
population. The high frequency of this age group might mean 
that there is a higher risk of HIV infection in this age group. The 
results were similar to the results of another study conducted in 
Lesotho[16], which reported that the 30-39 age group constituted 
up to 43.7% (n=255) of the study population.
The baseline variables of this study concurred with those of By-
grave et al.[17] at another site in Lesotho with respect to the effect 
of gender and age, but differed with respect to CD4 counts. 
The results of this study did not show that low baseline CD4 
count was a significant predictor for development of impaired 
renal function outcome. The reason could that the wider range 
of baseline CD4 counts in this study when compared to those 
of Bygraves et al.[17]
Tuberculosis was the most common infection at baseline. This 
was in line with the national TB statistics[18]. According to a 
report by the Government of Lesotho[18], about three-quarters 
(76%) of TB patients in Lesotho are co-infected with HIV.
Although the current guidelines do not indicate an upper age 
limit at which patients may not be given TDF, some patients 
older than 70 were put on TDF-containing regimens. Older pa-
tients are at a higher risk of having an impaired renal function 
outcome than younger patients because GFR decreases with 
age[19].
In this study, the four patients that developed severe renal 
impairment were taking ARVs and anti-TB drugs such as ri-
fampicin concurrently. Rifampicin is associated with interstitial 
Table 2: Logistic regression analysis of variables associated with impaired renal function outcomes.
Variable CrCl>50 (n=403) CrCl<50 (n=82)
Unadjusted OR 
(95% CI)
P-value Adjusted OR 
(95% CI)
P-value
Non-TDF 152 (87.6) 21 (12.4) 1 - 1 -
TDF group 251 (80.7) 61 (19.3) 1.7 (1.0-2.9) 0.054* 1.7 (0.9-3.2) 0.122
Age 20-29 61 (14.8) 3 (3.2) 1 - 1 -
Age 30-39 145 (37) 25 (31) 3.5 (1.0-12.0) 0.046** 3.2 (0.9-11.6) 0.077
Age 40-49 176 (43.7) 40 (48.8) 4.0 (1.1-13.9) 0.029** 3.5 (1.0-12.9) 0.060*
Age 50-59 176 (43.7) 40 (48.8) 5.6 (1.6-20.0) 0.008** 3.8 (1.0-14.9) 0.053*
Age 60-78 21 (5.2) 14 (17.1) 14.2 (3.7-54.6) <0.001** 9.1 (2.0-41.2) 0.004**
Male   232 (57.8) 60 (73.2) 1 - 1 -
Female 171 (42.4) 22 (26.8) 2.1 (1.2-3.6) 0.005** 2.2 (1.2-4.1) 0.016**
No HTN 267 (79.0) 39 (57.3) 1 - 1 -
HTN I or II 71 (21.0) 29 (42.7) 2.8 (1.6-4.8) <0.001** 2.2 (1.2-4.0) 0.009**
aCrCl>50 ml/min 347 (86.1) 50 (60.9) 1 - 1 -
aCrCl<50 ml/min 56 (13.9) 32 (39.0) 4.2 (2.5-7.1) <0.001** 1.6 (0.8-3.2) 0.218
HTN = Hypertension; CrCl = serum creatinine clearance in ml/min; aCrCl = baseline serum creatinine; OR= odds ratio; ** significant; * marginally significant.
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nephritis[20]. Impaired renal function outcomes cannot therefore 
be attributed to TDF alone. Rifampicin was however used in 
almost equal proportions between the TDF (35.6%, n=312) and 
non-TDF group (33.5%, n=173).
The proportion of patients with impaired (CrCl<50 ml/min) 
baseline renal namely was (56 or 18.0%). However, about 
twice as many patients (40 or 12.8%) developed impaired renal 
function outcomes in this study compared to those of Bygrave 
et al.[17] where 31 or 5.5% of patients with baseline CrCl>50 
ml/min developed renal function impairment. In the study of 
Bygrave et al.[17] only one patient (0.2%) developed severe im-
pairment and none developed end-stage renal disease. In this 
study, five patients (1.6%) in the TDF group developed severe 
renal impairment, and one patient in the TDF group developed 
end-stage renal disease. 
The use of ARVs containing TDF emerged as a marginally 
significant factor associated with impaired renal function out-
comes in the univariate logistic regression analysis (p=0.054) 
but was an insignificant factor (p=0.122) when adjusted for age 
(p<0.05), gender (p=0.005), high blood pressure (p=0.009), 
and body weight (p<0.05). The results indicated that TDF may 
not contribute significantly towards the development of renal 
impairment when compared to other variables such as female 
gender, high blood pressure, older age, or TDF may only worsen 
a pre-existing renal disorder as reported in South Africa[6]. 
The reported incidence of severe renal impairment following 
the use of TDF ranges from below 0.5% to just above 2%. The 
results of this study showed that 1.6% (n=312) of the patients 
developed severe renal impairment. The proportion with severe 
renal impairment was comparable to proportions reported in 
other studies. For example, a proportion of 1% was reported in 
the USA[1], 0.5% in the UK[21]; and 0.4% in India[22].
The major source of bias in this study included confounding 
variables, limited clinical data of the patients, and failure to 
account for the patients’ BMI data. Baseline CD4 counts and tu-
berculosis infection differed significantly between the TDF and 
the non-TDF groups at baseline. These two variables may have 
influenced the results of this study. Data on patients’ height, 
which is required for the calculation of body mass index (BMI), 
was not available. Lesotho does not measure patients’ heights 
as part of the ART programme. Therefore, the effect of BMI on 
kidney function which was not assessed in the study is another 
potential source of bias. 
Differing methodologies used in various studies may explain 
why the results of some studies differed. For example, a study 
in Italy[24] only included infants and adolescents but not adults. 
The impasse over TDF nephrotoxicity is likely to continue un-
less more studies are undertaken. 
CONCLUSION
The results of this study indicate that there is a weak associa-
tion between use of TDF and the development of renal impair-
ment (p=0.054) before controlling for other variables and no 
association when the results were controlled for other variables 
(p=0.122). The use of TDF does not contribute as much to renal 
impairment outcomes when compared to other variables such 
as hypertension, older age, and female gender. More research 
on the long term effects of TDF is recommended. Routine base-
line renal function screening should be adopted to prevent pa-
tients with impaired renal function receiving TDF.
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